Coya Therapeutics (NASDAQ:COYA – Get Free Report) and Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Coya Therapeutics and Aurinia Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Coya Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
| Aurinia Pharmaceuticals | 0 | 3 | 2 | 1 | 2.67 |
Coya Therapeutics currently has a consensus target price of $15.00, indicating a potential upside of 374.68%. Aurinia Pharmaceuticals has a consensus target price of $17.33, indicating a potential upside of 6.34%. Given Coya Therapeutics’ higher probable upside, research analysts plainly believe Coya Therapeutics is more favorable than Aurinia Pharmaceuticals.
Profitability
This table compares Coya Therapeutics and Aurinia Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Coya Therapeutics | -270.22% | -52.05% | -46.34% |
| Aurinia Pharmaceuticals | 97.68% | 22.99% | 17.99% |
Institutional and Insider Ownership
39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by company insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Coya Therapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.
Earnings & Valuation
This table compares Coya Therapeutics and Aurinia Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Coya Therapeutics | $7.95 million | 9.32 | -$21.23 million | ($1.07) | -2.95 |
| Aurinia Pharmaceuticals | $321.74 million | 6.79 | $287.20 million | $2.29 | 7.12 |
Aurinia Pharmaceuticals has higher revenue and earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Aurinia Pharmaceuticals beats Coya Therapeutics on 10 of the 14 factors compared between the two stocks.
About Coya Therapeutics
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction. The company’s lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient’s own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The Canadian company’s work has centered on therapies for conditions that can affect the kidneys and other organs. Its lead product, Lupkynis (voclosporin), is an oral medicine approved in the United States to treat adults with active lupus nephritis, a kidney complication of systemic lupus erythematosus. It is used in combination with background immunosuppressive therapy. Aurinia, formerly known as Isotechnika, developed voclosporin as a treatment for lupus nephritis.
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
